All In Biotech

Free tool

FAERS Monitor: Pavblu

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761298 or its brand name (Pavblu, Aflibercept-Ayyh). Reports on generic versions are filed under their own applications.

Reports

101

Serious

44

44% of reports

Hospitalization

4

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • treatment failure9
  • cough6
  • endophthalmitis6
  • eye pain6
  • off label use6
  • refusal of treatment by patient5
  • device physical property issue4
  • drug ineffective4
  • headache4
  • uveitis4
  • blindness unilateral3
  • cerebrovascular accident3
  • death3
  • diabetes mellitus3
  • diarrhoea3

Reports by year received

View as table
YearReports
202540
202661

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endophthalmitisSignal6208.595.91,039
refusal of treatment by patientSignal5159.667.9637
device physical property issueSignal4108.841.6326
uveitisSignal461.423.5181
blindness unilateralSignal344.314.587
treatment failureSignal922.612.1166
eye painSignal622.110.2101
diabetes mellitusSignal38.22.712
coughSignal64.52.113
cerebrovascular accident33.71.24
off label use61.40.70
headache41.30.50
diarrhoea31.00.30
death30.70.20
drug ineffective40.60.21

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.